Yoshiyasu Nagashima
Overview
Explore the profile of Yoshiyasu Nagashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
0
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagashima Y, Tochinai R, Sekizawa S, Kato D, Nakagawa T, Tsuru Y, et al.
J Toxicol Pathol
. 2023 Aug;
36(3):151-158.
PMID: 37577366
Combretastatin A4 disodium phosphate (CA4DP) is a prodrug of combretastatin A4 (CA4), a microtubule-disassembling agent that exhibits antitumor effects by inhibiting tumor cell proliferation and inducing morphological changes and apoptosis...
2.
Tochinai R, Nagashima Y, Sekizawa S, Kuwahara M
J Appl Toxicol
. 2023 Jul;
44(1):96-106.
PMID: 37496236
Microtubule polymerization inhibitors (MPIs) have long been used as anticancer agents because they inhibit mitosis. Microtubules are thought to play an important role in the migration of tumor cells and...
3.
Orihara H, Ma M, Nagashima Y, Tochinai R, Sekizawa S, Kato D, et al.
Biomed Pharmacother
. 2023 Feb;
160:114353.
PMID: 36736274
Combretastatin A4 (CA4) inhibits microtubule polymerization, and clinical trials of the prodrug, CA4 disodium phosphate (CA4DP), as an anti-cancer agent have been conducted. However, CA4DP has not been marketed to...